Related Experiment Video

Updated: Aug 15, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Quinapril in chronic heart failure

D B Northridge1, H J Dargie

  • 1Department of Cardiology, Western Infirmary, Glasgow, Scotland.

American Journal of Hypertension
|November 1, 1990
PubMed

Insights

Angiotensin converting enzyme inhibitors effectively treat chronic heart failure, improving symptoms and exercise capacity. Quinapril, a new ACE inhibitor, showed promising results in a study for mild to moderate heart failure patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Angiotensin converting enzyme (ACE) inhibitors are standard therapy for chronic heart failure (CHF).
  • These drugs offer hemodynamic benefits without reflex tachycardia or tolerance.
  • ACE inhibitors improve symptoms, exercise capacity, and prognosis in heart failure patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of quinapril, a novel ACE inhibitor, in patients with chronic heart failure.
  • To assess the dose-response relationship of quinapril in improving clinical status and exercise capacity.

Main Methods:

  • A large, multicenter, randomized, placebo-controlled study.
  • 225 patients with mild to moderate CHF were enrolled.
  • Treatment involved daily doses of quinapril ranging from 10 to 40 mg.

Main Results:

  • Quinapril significantly improved clinical status and exercise capacity in a dose-dependent manner.
  • No significant difference in side effect incidence was observed compared to placebo.
  • The hemodynamic effects of quinapril were consistent with other ACE inhibitors.

Conclusions:

  • Quinapril is a promising ACE inhibitor for treating chronic heart failure.
  • Further clinical investigation is warranted to confirm its long-term efficacy and safety.
  • Its intermediate half-life makes it suitable for CHF management.

More Related Videos

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models07:49

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

Published on: July 21, 2023

Clinical Application of Phase Angle and BIVA Z-Score Analyses in Patients Admitted to an Emergency Department with Acute Heart Failure04:05

Clinical Application of Phase Angle and BIVA Z-Score Analyses in Patients Admitted to an Emergency Department with Acute Heart Failure

Published on: June 30, 2023

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.